secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001558370-25-001679
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q4 net loss $96.6M, revenue $9.2M; cash $203.9M; pipeline catalysts in H1 2025
--------------------------------------------------------------------------------

- Net loss $96.6M in Q4 2024 vs $1.5M in Q4 2023; included $86.9M in-process R&D charge from bosakitug license.
- Revenue $9.2M in Q4 2024 vs $17.6M in Q4 2023; full year revenue $18.7M vs $31.2M.
- Cash, equivalents and marketable securities $203.9M at Dec 31, 2024; cash runway expected into 2028.
- Phase 2 data from partner CTTQ in severe asthma and CRSwNP expected H1 2025; Phase 2b for bosakitug in AD enrollment H1 2025.
- Leadership changes: Neal Walker named CEO; Hugh Davis appointed President and COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025001679/0001558370-25-001679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025001679/acrs-20250227x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-001679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer